PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2 | Salk Institute

Show Me

Attempt to ban vaccine passports in Arizona fails

Show Me

BUSTED: CDC Caught Manipulating Data to Hide New COVID Cases Among those Who Were Already Vaxxed

Show Me

200+ scientists, doctors promote vitamin D to ward off Covid-19

Show Me

U.S. Nonprofit with Ties to Wuhan Lab Violated Federal Law by Failing to Disclose Taxpayer Funding, Complaint Alleges

Show Me

Dr. Fauci Backed Controversial Wuhan Lab with U.S. Dollars for Risky Coronavirus Research

Show Me

No One Can Find The Animal That Gave People Covid-19

Show Me

Data Leak Shows Regulators Had Major Concerns About Pfizer’s mRNA Vaccine

Show Me

Top Researchers Are Calling For A Real Investigation Into The Origin Of Covid-19

Show Me

Worse Than the Disease? Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID-19 | International Journal of Vaccine Theory, Practice, and Research

Show Me

The Novel Coronavirus’ Spike Protein Plays Additional Key Role In Illness

Show Me

MIT Research Scientist Dr. Stephanie Seneff On The mRNA Vaccine | “It’s an insanely reckless thing that they’ve done.” | Video: 1 Hour 23 Minutes 33 Seconds

Show Me

Covid-19 Vaccine Regret | Video: 4 Minutes 55 Seconds

Show Me

Love Can Be Real | “Childhood Sweethearts Married for 63 Years Died Within 72 Hours of Each Other”

Show Me

‘Drag Queens in Training’: NYC Department of Education Children’s Show Features 12 Minutes of ‘Lil Miss Hot Mess’ Reading and Dancing

Show Me

Why the American People Have Turned Against Biden

Show Me

New York to open vaccination pop-ups at airports for visitors, locals

Show Me

Singapore Closes Two Shopping Malls Amid Surge In Covid Cases

Show Me

Ron DeSantis Hits Bush’s Amnesty Coalition: GOP Must Reject Open Borders

Show Me

N.J. Democrat Rep. Malinowski profits on COVID-related stocks, draws congressional ethics complaints

Show Me

Texas Senate Passes Bill That Bans Critical Race Theory From Classrooms

Show Me

For Japanese Americans imprisoned at Amache internment camp, lifetimes of silence and undeserved shame

Show Me

Trump statement on Arizona Attorney General Mark Brnovich

Show Me

Dept of Labor and OSHA Reverse Course, Will Not Enforce Employer Responsibility to Report COVID Vaccination Injuries

Show Me

Professor wants John Steinbeck’s estate to publish secret werewolf novel

Show Me

New COVID-19 cases plummet to lowest levels since last June

Show Me

SHOCKING VIDEO: Sunday School Teacher Arrested for Not Wearing Mask to School Board Meeting

Show Me

‘1619 Project’ Has No Place in South Dakota, Kristi Noem Says

Show Me

CNN Drops Rick Santorum After Dismissive Comments About Native Americans

Show Me

Fake News Is Real & Extremely Harmful To The Public | “How the BBC lied and lied about the MoS scoop which exposed the forged bank statements”

Show Me

Antisemitism and attacks on Jews fueled by social media, experts say

Show Me

Bannon’s War Room | Saturday Edition Hour 1 | Recorded May 22, 2021 | Video: 48 Minutes 35 Seconds

Show Me

Bannon’s War Room | Saturday Edition Hour 2 | Recorded May 22, 2021 | Video: 48 Minutes 20 Seconds

Show Me

Coming To A School Near You | Child Slapped For Allowing Mask To Fall Below Her Nose

Show Me

Always Follow The Money | “TEXAS: Abbott, Patrick, House Speaker Received $250K+ From Clinic That Chemically Castrates ‘Transgender’ Kids”

Show Me

BREAKING, Judge Orders Physical Review of Fulton County Ballots – Expert Witness Testified High Percentage Discrepancy in Ballot Batches

Show Me

The New York Times Exposes and Cuts Ties With Fusion GPS

Show Me

Physicians Group Files Motion to Halt Use of COVID Vaccines in Children

Show Me

Cuba: Artist Named Prisoner of Conscience

Show Me

Dozens Arrested After Conflict in Gaza Leads to Clashes in Times Square

Show Me